Related Experiment Video

Updated: Nov 29, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.8K

Erratum: LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression

Ziran Wang, Wenwei Yu, Yawen Qiang

    Molecular Therapy Oncolytics
    |November 19, 2020
    PubMed

    Abstract:

    [This corrects the article DOI: 10.1016/j.omto.2020.05.006.].

    More Related Videos

    Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
    11:06

    Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

    Published on: September 20, 2017

    6.4K
    Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
    07:16

    Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

    Published on: September 13, 2018

    20.4K

    Related Experiment Videos

    Last Updated: Nov 29, 2025

    Assays for Validating Histone Acetyltransferase Inhibitors
    09:11

    Assays for Validating Histone Acetyltransferase Inhibitors

    Published on: August 6, 2020

    6.8K
    Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
    11:06

    Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

    Published on: September 20, 2017

    6.4K
    Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
    07:16

    Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

    Published on: September 13, 2018

    20.4K

    Related Concept Videos

    Abnormal Proliferation02:23

    Abnormal Proliferation

    4.9K
    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    4.9K

    Articles linked to this work by shared authors, journal, and citation graph.

    Intrinsically Inhibiting Singlet Quenching of Organic Sensitizers for Enhanced CO2 Photoreduction.

    Angewandte Chemie (International ed. in English)·2026

    Impact of brain anisotropy on transcranial temporal interference stimulation: numerical analysis toward reliable montage optimization.

    Biomedical engineering letters·2026

    Human-relevant co-exposure to 6:2 Cl-PFESA and PFHxS impairs sperm motility and blood-testis barrier integrity in male mice: Evaluation of combined effects.

    Journal of hazardous materials·2026

    Study on Gut Microbiota Adaptation of Plateau Zokor (Eospalax baileyi) to High-Altitude Environments.

    Microorganisms·2026

    Microbial tryptophan-IPA axis mediates 6:2 chlorinated polyfluorinated ether sulfonate (6:2Cl-PFESA)-induced gut-brain dysfunction and neurobehavioral impairments.

    Environment international·2026

    Crack-Interlocked Metal/Elastomer Interfaces for Preload-Adapted Backside Pressure Sensing.

    ACS applied materials & interfaces·2026

    Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML.

    Molecular therapy oncolytics·2025

    The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges.

    Molecular therapy oncolytics·2023

    Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.

    Molecular therapy oncolytics·2023

    Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer.

    Molecular therapy oncolytics·2023

    Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers.

    Molecular therapy oncolytics·2023

    Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma.

    Molecular therapy oncolytics·2023
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us